Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.66 |
| ▸ | P2RX7 | Q99572 | 13/20 | 0.54 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7177946 | 0.88 | ALDH1A1 (0.61) | ALDH1A1P2RX7HSD11B1L3MBTL1TSHR | |
| SCHEMBL16430484 | 0.87 | P2RX7 (0.54) | ALDH1A1P2RX7HSD11B1 | |
| SCHEMBL15577224 | 0.85 | TSHR (0.63) | ALDH1A1P2RX7HSD11B1L3MBTL1TSHR | |
| SCHEMBL624643 | 0.85 | HSD11B1 (0.63) | ALDH1A1HSD11B1L3MBTL1TSHR | |
| SCHEMBL3633468 | 0.85 | HSD11B1 (0.68) | ALDH1A1P2RX7HSD11B1L3MBTL1 | |
| SCHEMBL18111428 | 0.84 | HSD11B1 (0.71) | ALDH1A1P2RX7HSD11B1L3MBTL1TSHR | |
| SCHEMBL5365203 | 0.82 | P2RX7 (0.56) | ALDH1A1P2RX7L3MBTL1 | |
| SCHEMBL21214447 | 0.81 | ALDH1A1 (0.55) | ALDH1A1HSD11B1L3MBTL1TSHR | |
| SCHEMBL22089167 | 0.80 | HSD11B1 (0.50) | ALDH1A1P2RX7HSD11B1L3MBTL1TSHR | |
| SCHEMBL16565616 | 0.78 | ALDH1A1 (0.56) | ALDH1A1P2RX7HSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3027593-B1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3027593-B1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2020-06-10 | — | — | EP | disclosed |
| EP-3116862-B1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-04-17 | — | — | EP | disclosed |
| EP-3116862-B1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME (US) | 2019-04-17 | — | — | EP | disclosed |
| US-10138255-B2 | Piperazine derivatives as HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2018-11-27 | — | — | US | disclosed |
| US-9840478-B2 | Piperazine derivatives as HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| US-9840478-B2 | Piperazine derivatives as HIV protease inhibitors | MERCK SHARP & DOHME CORP. (US) | 2017-12-12 | — | — | US | disclosed |
| US-20170073354-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-03-16 | — | — | US | disclosed |
| US-20170073354-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2017-03-16 | — | — | US | disclosed |
| EP-3116862-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2017-01-18 | — | — | EP | disclosed |
| WO-2015135091-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015138220-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015017393-A2 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2015013835-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2015017393-A2 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-02-05 | — | — | WO | disclosed |
| WO-2015013835-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2015-02-05 | — | — | WO | disclosed |
| US-7166616-B2 | Substituted alkanoic acids | AVENTIS PHARMA LIMITED (GB) | 2007-01-23 | — | — | US | disclosed |
| US-20040006056-A1 | For therapy of disease states capable of being modulated by the inhibition of cell adhesion; therapy of asthma | AVENTIS PHARMA LIMITED (GB) | 2004-01-08 | — | — | US | disclosed |
| EP-1330432-A2 | SUBSTITUTED ALKANOIC ACIDS | Aventis Pharma Limited (GB) | 2003-07-30 | — | — | EP | disclosed |
| WO-2002036553-A2 | SUBSTITUTED ALKANOIC ACIDS | AVENTIS PHARMA LIMITED (GB) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073354-A1 | PIPERAZINE DERIVATIVES AS HIV PROTEASE INHIBITORS | PREP, CTSZ, PEPD | ALDH1A1 955/4885P2RX7 1340/4885HSD11B1 1862/4885 |
| US-20040006056-A1 | For therapy of disease states capable of being modulated by the inhibition of cell adhesion; therapy of asthma | VCAM1, LTB4R, ITGA1 | ALDH1A1 354/4885P2RX7 2622/4885HSD11B1 453/4885 |
| US-10138255-B2 | Piperazine derivatives as HIV protease inhibitors | PREP, CTSZ, PEPD | ALDH1A1 955/4885P2RX7 1340/4885HSD11B1 1862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.